Published in Blood Weekly, October 12th, 2006
This is a US$143 million project for Cangene under Project BioShield to produce 10,000 doses of anthrax immune globulin (AIG) to be made available for treating inhalational anthrax. Under the contract Cangene will provide AIG to the U.S. Strategic National Stockpile until 2009.
"Once again this project shows that Life Therapeutics is at the forefront of the plasma collection business," said Dr. Hari Nair, CEO and president of Life Therapeutics. "Assisting with this important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.